Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets
Dräger O, Metz K, Busch M, Dünker N (2022)
Molecular Oncology 16(4): 957-981.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Dräger, Oliver;
Metz, Klaus;
Busch, Maike;
Dünker, Nicole
Abstract / Bemerkung
The study presented focuses on the role of the neuronal cell adhesion molecule L1 cell adhesion molecule (L1CAM) in retinoblastoma (RB), the most common malignant intraocular childhood tumor. L1CAM is differentially expressed in a variety of human cancers and has been suggested as a promising therapeutic target. We likewise observed differential expression patterns for L1CAM in RB cell lines and patient samples. The two proteases involved in ectodomain shedding of L1CAM (L1CAM sheddases: ADAM10 and ADAM17) were likewise differentially expressed in the RB cell lines investigated, and an involvement in L1CAM processing in RB cells could be verified. We also identified ezrin, galectin‐3, and fibroblast growth factor basic as L1CAM signaling target genes in RB cells. LentiviralL1CAMknockdown induced apoptosis and reduced cell viability, proliferation, growth, and colony formation capacity of RB cells, whereasL1CAM‐overexpressing RB cells displayed the opposite effects. Chicken chorioallantoic membrane assays revealed thatL1CAMdepletion decreases the tumorigenic and migration potential of RB cellsin vivo. Moreover,L1CAMdepletion decreased viability and tumor growth of etoposide‐resistant RB cell lines upon etoposide treatmentin vitroandin vivo. Thus, L1CAM and its processing sheddases are potential novel targets for future therapeutic RB approaches.
Erscheinungsjahr
2022
Zeitschriftentitel
Molecular Oncology
Band
16
Ausgabe
4
Seite(n)
957-981
ISSN
1574-7891
eISSN
1878-0261
Page URI
https://pub.uni-bielefeld.de/record/2984787
Zitieren
Dräger O, Metz K, Busch M, Dünker N. Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets. Molecular Oncology. 2022;16(4):957-981.
Dräger, O., Metz, K., Busch, M., & Dünker, N. (2022). Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets. Molecular Oncology, 16(4), 957-981. https://doi.org/10.1002/1878-0261.13054
Dräger, Oliver, Metz, Klaus, Busch, Maike, and Dünker, Nicole. 2022. “Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets”. Molecular Oncology 16 (4): 957-981.
Dräger, O., Metz, K., Busch, M., and Dünker, N. (2022). Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets. Molecular Oncology 16, 957-981.
Dräger, O., et al., 2022. Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets. Molecular Oncology, 16(4), p 957-981.
O. Dräger, et al., “Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets”, Molecular Oncology, vol. 16, 2022, pp. 957-981.
Dräger, O., Metz, K., Busch, M., Dünker, N.: Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets. Molecular Oncology. 16, 957-981 (2022).
Dräger, Oliver, Metz, Klaus, Busch, Maike, and Dünker, Nicole. “Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets”. Molecular Oncology 16.4 (2022): 957-981.